Furthermore, the role of VEGF inhibition to delay erlotinib resistance in patients with EGFR mutation NSCLC recently received renewed interest with publication of a positive phase II trial looking at the addition of the VEGF antibody bevacizumab to single-agent erlotinib as a first-line strategy [12]. Here, VEGFA is linked to non-small cell lung carcinoma.